The CD40/CD40L axis in glioma progression and therapy

Role of CD154 in cancer pathogenesis and immunotherapy

(2015) Ghada S. Hassan et al.   CANCER TREATMENT REVIEWS

CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models

(2015) Masashi Chonan et al.   NEURO-ONCOLOGY

Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells

(2014) Akemi Kosaka et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials

(2014) Sufia Butt Hassan et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination

(2013) I. Melero et al.   CLINICAL CANCER RESEARCH

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

(2013) Stephanie M Pyonteck et al.   NATURE MEDICINE

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma

(2010) Fang Xie et al.   JOURNAL OF NEUROIMMUNOLOGY